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Background: Given the estimate that 30% of our genes are controlled by microRNAs, it is essential that we
understand the precise relationship between microRNAs and their targets. OncomiRs are microRNAs (miRNAs) that
have been frequently shown to be deregulated in cancer. However, although several oncomiRs have been
identified and characterized, there is as yet no comprehensive compilation of this data which has rendered it
underutilized by cancer biologists. There is therefore an unmet need in generating bioinformatic platforms to speed
the identification of novel therapeutic targets.
Description: We describe here OncomiRdbB, a comprehensive database of oncomiRs mined from different existing
databases for mouse and humans along with novel oncomiRs that we have validated in human breast cancer
samples. The database also lists their respective predicted targets, identified using miRanda, along with their IDs,
sequences, chromosome location and detailed description. This database facilitates querying by search strings
including microRNA name, sequence, accession number, target genes and organisms. The microRNA networks and
their hubs with respective targets at 3'UTR, 5'UTR and exons of different pathway genes were also deciphered using
the 'R' algorithm.
Conclusion: OncomiRdbB is a comprehensive and integrated database of oncomiRs and their targets in breast
cancer with multiple query options which will help enhance both understanding of the biology of breast cancer
and the development of new and innovative microRNA based diagnostic tools and targets of therapeutic
significance. OncomiRdbB is freely available for download through the URL link http://tdb.ccmb.res.in/OncomiRdbB/
index.htm.
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Although microRNAs were discovered two decades ago,
their importance as an abundant class of regulatory non-
coding RNAs came to light only after their rediscovery
by Reinhart et al., in 2000 [1]. To date, thousands of
miRNAs have been identified across a range of human
diseases and have been shown to be deregulated in the
majority of cancers [2]. Identifying the signatures of onco-
miRs in human cancer samples is extremely difficult due
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reproduction in any medium, provided the ormicroRNAs has proven difficult due to their extremely
small size and complexity of spatial and temporal expres-
sion patterns. However, the precursor transcripts of ~70-80
nt with a characteristic stem-loop fold back structure from
which the miRNAs are derived, are conserved and this typ-
ical structure of precursor-microRNAs enables its identifi-
cation through computational tools.
Finding the targets of a given miRNA is as important
as identifying the miRNA itself to know the gene(s) it
controls hence infer possible biological function through
either negative or positive regulation of the target
gene(s) [3]. Computational prediction of target genes for
miRNAs in animals is a challenging task for both experi-
mental and computational groups, due to the complexity
in miRNA target recognition [4]. Eventhough perfectl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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quired for target recognition and interaction, a small
region in the 5′end (termed the seed region “position
2-8”) of miRNA is apparently needed for a near perfect
base-pairing with its 3′UTR to inhibit the translation of
mRNA [5].
Several databases of miRNAs, based on sequence an-
notation and miRNA genomics such as miRBase, [6]
miRNAMap2.0 [7], miRGen [8], miRGator v2.0 [9],
miRecords [10] have been developed. Amongst these da-
tabases, miRBase serves as a central database of mature
miRNA sequences. MicroCosm, PhenomiR 2.0 [11] and
mir2Disease [12] provide data pertinent to various dis-
eases, whilst TargetScan [13], PicTar [14] and TargetMiner
[15] are databases based on algorithms designed for
microRNA target prediction for the complementary base-
pairing in the seed region of the targets. TarBase [16] is a
resource of experimentally validated microRNA targets,
while RNAhybrid [17] is a resource based on calculation
and hybridization between miRNA and mRNA. Recently,
S-MED database has been created [18], which gives details
of oncomiR expression profiles in sarcomas. However,
there is currently no comprehensive oncomiR database for
breast cancer that will provide an overview of microRNAs,
their targets and the pathways that are regulated by them
during breast cancer development. Our aim was to de-
velop a database compiling all oncomiRs and their target
genes involved in breast cancer and validate them using
human breast cancer samples. The known oncomiRs re-
sponsible for breast cancer in two mammalian genomes,
human and mouse were obtained from different databases
including MicroCosm, PhenomiR and mir2Disease. The
target genes were taken from the signaling pathways that
are known to be affected during breast cancer. By using
the miRanda algorithm [19], target genes were predicted
for both human and mouse. Prediction programs includ-
ing PicTar and TargetScan were used as additional
sources. In nutshell, OncomiRdbB comprises of 782 hu-
man microRNAs and 246 murine microRNAs, along with
711 and 490 targets for both genomes respectively. It also
provides the precise target location within the 3′UTR, 5′
UTR or exon regions of the target genes. A proportion of
the microRNAs have also been validated in breast cancer
tissues using Taqman Low Density Arrays (TLDA).
Amongst these, 34 microRNAs have not previously been
reported to be associated with human breast cancer in any
database. Hence, this is the first report of these novel
microRNAs associated with breast cancer. Finally, using the
‘R’ algorithm and ‘GeneGo MetaCore’ (www.genego.com)
we have characterized some of these microRNAs and their
target interactions, generating examples of delineated net-
works and hubs of microRNA-target interaction. We envis-
age these network analyses will further support the
identification of oncogenic targets of therapeutic value.Construction
Mining of microRNAs and finding their targets
MicroRNAs of both human and mouse genomes were
retrieved from different databases including miRBase,
PhenomiR 2.0 and miR2Disease. A Perl subroutine was
written to automate the retrieval and filtering of miRBase
sequences. In order to find out the targets of these micro-
RNAs, genes of various key signaling pathways including
Wnt, JAKSTAT, Notch, Apoptosis, VEGF and MAPK were
downloaded from KEGG (Kyoto Encyclopedia of Genes
and Genomes) miRBase (MicroCosm), Cancer Gene Ex-
pression Data Base (CGED) [20]. The 3′UTR, 5′UTR and
exon sequences of these genes were then extracted from
the Ensembl database in FASTA format using the BioMart
tool. miRanda was used at 3 different energy levels (EL-
15,-20 and −25) to predict putative targets for the miRNAs
involved in breast cancer at the 3′UTR, 5′UTR and
exonic regions of the genes of the different pathways.
The parameters used for the search were at the cutoff
score of 120.
The miRanda software was initially designed to predict
miRNA target genes in Drosophila. It is similar to the
alignment proposed by Smith and Waterman [21], where
scores were based on sequence complementarity and
not on sequence identity. These targets were further
confirmed using the TargetScan and PicTar algorithms.Experimental validation using Taqman Low
Density Arrays
Taqman Low Density Array (TLDA) was performed with
50 individual human samples followed by confirmation
with LNA arrays. Reverse Transcription reaction was car-
ried out using TaqMan MicroRNA Reverse Transcription
Kit (Applied Biosystems, USA) followed by PCR Reaction.
Real-time PCR was performed using Applied Biosystems
7900- TLDA Real-Time PCR System. Each TaqMan Assay
was run in quadruplicate. All the samples displayed good
RIN value, linearity (R2 > 0.96), good abundance (average
CT range 22–28) and NTC CT >38. MicroRNA profiling
was done using TaqMan MicroRNA Arrays, which con-
tains 667 human microRNAs covering Sanger miRBase
version10. A pre amplification step of cDNA with preamp
megaplex pool primers was performed to enhance the
ability to detect miRNAs with low expression. The TaqMan
human microRNA arrays consisted of 2 plates: pool A and
pool B. RNU 46 and RNU 48 were used as endogenous
controls and are included for data normalization. One
TaqMan microRNA Assay, not related to human, was also
included as a negative control. The set enabled accurate
quantification of 667 human microRNAs. Reverse tran-
scription followed by PCR reactions were carried out in
ABI 7900 HT. The results were analysed using spotfire
(statminer) software and the data was normalized using
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were represented as log 10 2
- Δ Δ CT.
Pathway analysis of miRNA-Target
Functional enrichment analysis of microRNAs and their
target genes was performed to identify unique, similar
and common sets of genes/proteins. Enrichment analysis
of miRNAs and their targets in oncogenic signaling
pathways was performed using the GeneGo MetaCore
software. This software is a web-based program and per-
forms functional analysis of experimental data or com-
putationally compiled datasets on ontologies such as
GeneGo process networks, GeneGo diseases, disease
biomarkers, gene ontology processes (GO) metabolic
processes, various signaling pathways, canonical path-
ways, protein-DNA interactions, protein-protein interac-
tions etc. This enrichment analysis creates a degree of
relevance of the datasets to the GeneGo MetaCore suite,
defined by p-values where lower p-values were assigned
higher priorities. The statistical enrichment analysis of
miRNAs and their targets were performed based on the
p-values generated. We have used ClustalX to identify
sequence similarity with a conserved biological function
of miRNAs in breast cancer.
‘R’ algorithm
‘R’ is an open source statistical language for statistical
analysis and graphics. It provides a wide variety of statis-
tical and graphical techniques (linear and nonlinear
modeling, statistical tests, time series analysis, classifica-
tion, matrix manipulation and clustering). In this study
R (v2.14) packages (ggplot2) [22] were used for building
the network of miRNA and their target genes. To build-
up the miRNA-target interaction network we con-
structed a matrix using the binary concept 0 & 1. As an
example, hits between microRNAs and specific target
genes were assigned a binary value of 1, while 0 implies
absence of recognition. This matrix was uploaded in ‘R’
which generated a graphical miRNA-target interaction
network. The ‘R’ program was used to generate such
types of network where a single miRNA was hitting sev-
eral targets or where several miRNAs hit single target in
each oncogenic signaling pathway.
Contents
miRNAs responsible for breast cancer
The mined miRNAs were classified as breast cancer
miRNAs based on their complementarity to the target
genes of different oncogenic pathways (MicroCosm)
deregulated in breast cancer. This was further confirmed
using miRanda, TargetScan and PicTar (Figure 1).
A comparison between OncomiRdbB and existing data-
bases demonstrated the utility of integrating various
databases into one comprehensive database (Figure 2).A phylogenetic functional relationship between micro-
RNAs of human and mouse was established by aligning
the sequences using ClustalX. A conserved biological
function of breast cancer microRNAs between mice and
human genomes was observed after clustering both data
sets. In the cladogram, branches from the same node
represent descendents of a similar ancestor or cluster of
the same family indicating their origin from a common
ancestor. For example, hsa-miR-145, miR-151-3p and
miR-30 families align with their mmu-miR counterparts
indicating a conserved biological function in breast can-
cer development in both the genomes (Additional file 1:
Figure S1). We retrieved a total of 782 human and 246
mouse microRNAs and their respective sequences asso-
ciated with breast cancer from existing miRNA data-
bases including miRBase, miR2Disease and PhenomiR.
We have validated these miRNAs with two different
platforms, Taqman low density arrays consisting of 667
human microRNAs (version 10) and LNA arrays using
human breast cancer samples of grade 2 and grade 3
each consisting of Stages I to III. Approximately 400
significant and valid miRNAs lighted up in one or the
other grades/stages classifying them as breast cancer
microRNAs.
Identification of novel microRNAs using Taqman Low
Density Arrays and LNA microarray
Among the 400 significant miRNAs validated experi-
mentally using 2 array platforms, a set of 34 novel
miRNAs was identified as novel breast cancer miRNAs
since they were not classified as breast cancer miRNAs
earlier. The targets of these miRNAs were also identified
using miRanda at 3 energy levels, EL-15, -20 and −25
and the most stringent ones (EL −25) are listed in
Table 1. These miRNAs and their targets were impli-
cated in various signaling pathways, as revealed by the
MetaCore software (Figure 3a and Table 1). The network
of interactions showed involvement of key oncogenic
signaling pathways like Wnt, JAK-STAT, PI3K and AKT.
A spectrum of miRNAs including miR-337-5p, miR-17-1,
miR-15a, miR-491-5p, miR-339, miR-337-3p, miR-241,
miR-19a were predicted to down regulate oncogenic
targets like TGFβ, BCLXW, BCL-Xl, STATs, c-MYC and
SMAD (as represented by red lines). It was also observed
that miR-141 positively controls the canonical pathway in-
volving SP1 transcription factor via TGFβ, receptor, which
activates matrix metalloproteinases, the deregulation of
which plays a crucial role in metastasis.
miRNA targets
The miRanda program was used to predict microRNA
targets in the various oncogenic signaling pathways. This
algorithm was run at energy level EL-15 and 711 genes in
human and 490 in mice were identified. The stringency
Figure 1 Schematic illustration of construction of OncomirdbB using different bioinformatics approaches. MicroRNAs were mined from
different databases like miRbase, PhenomiR2.0 and miR2Disease. In order to find targets for these miRNAs, different pathway genes were
downloaded from KEGG database and removed the repeated entries by using Perl script. We used miRanda for finding the targets at different
energy levels.
Figure 2 Comparison of human and mouse miRNAs from
different databases with oncomiRdbB. Human and mouse
miRNAs were mined from various databases listed and compiled as
OncomiRdbB. This database has a maximum number of miRNAs
compared to MicroCosm, PhenomiR and miR2Disease which list 460,
322 and 83 human miRNAs and 183, 63 and 0 mouse
microRNAs respectively.
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EL-20 and EL-25, in order to increase the accuracy and to
identify fewer targets with increased specificity (Figure 4a).
By computing the ratio of miRNA targets with the total
number of genes in the respective pathways, the percent-
age cooperation among different pathways including the
Notch, VEGF, Wnt, MAPK, Apoptotic and JAK-STAT
pathways was deciphered and thus their potential involve-
ment in breast cancer development. Notch signaling path-
way was found to have the highest (~50%) percentage of
cooperativity between the novel miRNAs and their signal-
ing molecules compared to other pathways analyzed in
both murine and human hosts (Figure 4b).
We next characterized microRNA target locations
within the genes and found that almost 70% of miRNAs
target the 3′UTR, 10% of them target the 5′UTR and
another 10% were found to target the exons. 5% of
miRNAs targeted exons at their 3′ and 5′ UTR, respect-
ively within the gene and the remaining 5% targeted
5′UTR, 3′UTR & exons (Figure 5a). There were many
mRNAs which were targeted by multiple miRNAs and
among such targets, the Dvl3 gene in the wnt pathway
Table 1 Lists the experimentally validated novel microRNAs and their putative targets in different signaling pathways
at EL −25 ΔG kcal/mol
a.
Novel miRNA Targets(Jak-Stat)
hsa-miR-193b-5p SOCS-2, AKAP13, AKT2, BCL2L1, CLCF1, IL10RA, IL10RB, JAK3, LIF, PIAS4,PIK3R2, PIK3R5, PRLR, PTPN11, SOCS7, STAT5B,
TSLP, TYK2
hsa-miR-296-3p AKT2, BCL2L1, CSF3, GRB2, IFNGR2, IL10RA, IL11, IL11RA, IL9R, PIK3CB, PIK3R2, PIK3R5,PRKAR2A, PTPN6, STAT5A, STAT6,
TSLP, TYK2
hsa-miR-296-5p CREBBP, GRB2, PIAS2, PTPN11, SOCS3, STAT6
hsa-miR-339-3p IL20RA, SOCS2, STAT5A, CLCF1, GH2, GHR, IL2RB, IL4R, IL6R, LIF
hsa-miR-491-5p CBLB, CISH, CSF3R, PIK3R2, PTPN6, SOCS7, SPRY4, TYK2, AKT1, IKBKG, PIK3R5, SERF2, AKAP13, CSF3, IFNAR2, IL15RA,
IL2RB, IRF9, LEP, PIK3R5, PRLR, SOCS2, SPRY3, STAT6, STS
hsa-miR-623 AKAP13, AKT2, BCAS1, CSF3, CSF3R, GRB2, IFNAR2, IL10RA, IL11RA, IL28RA, IL4R, IL6ST, PIK3R2, PIK3R5, SASH1, SOCS3,
SPRY4, STAT5A, STAT6, TYK2
hsa-miR-639 CCND1, IL2RB, PIAS4, PRLR, AKAP13, BCL2L1, CBL, CISH, CNTFR, CSF2RB, CSF3, GRB2
hsa-miR-770-5p IL4R, PIK3R3, AKAP13, AKT2, CBL, CNTFR, CSF3, IL11RA, IL6ST, IL7R, PIK3R5, PTPN11, SOCS2, STAT5A, STAT5B, STAT6, STS,
TYK2
hsa-miR-941 CSF2RA, CTF1, IFNAR1, IFNAR2, IL10RA, IL10RB, IL11RA, IL28RA, LIF, OSM, PIK3CA, PIK3R2, PRKAR2A, PRLR, STAT5A,
SOCS3, SPRED2
hsa-miR-15a-3p BCAS1, FZD4, PIK3R1, AKAP13, BCAS1, CISH, CSF2, CSF3R, GRB2, IL13, IL13RA1, STAT5A, TYK2
hsa-miR-141-5p AKT2, BCL2, PRKAR1B, TRAF2, XIAP, CISH, IL22RA2, PIK3R3, PIM1, STAT2, STAT6
hsa-miR-148b-5p IFNAR2, JAK1, DFFA, IFNAR2, JAK1
hsa-miR-17-3p EXOG, IRAK3, TRAF2, CBL, STAT1 IL15RA, IL19, STAT6
hsa-miR-188-3p AKT1, OSMR, SPRY2, SPRY4, CCND1,IL10RA, CBLB, CISH, CNTFR, CSF2RB, IL13, IL13RA1, IL6, IL9R, PTPN6, SPRY3, STAT3,
TYK2
hsa-miR-218-2-3p AKAP13, AKT2, PIM1, STAT5A, TYK2, CSF2RB, CSF3R
hsa-miR-219-1-3p EXOG, AKAP13, AKAP13, IL7R, PIM1, SPRY3, TSLP, IL11, IL13RA1, MATR3, IL19
hsa-miR-24-1-5p PIK3R1, IL19, CSF2RB, DFFB, PIK3R1, NRG1
hsa-miR-329 SOCS2, IL10RA, IL4R, GRB2, IFNAR2, IL11RA , JAK3
hsa-miR-337-5p AKT2, CBL, IL10RB, TNFRSF10B, AKAP13, AKT1, CSF2RB, IL10RA, IL13RA1, PIK3R5, STAT6, CTF1, IL28RA, JAK3, STAT5A,
STAT5B, STS, TYK2 , MVP
hsa-miR-506-3p PIAS2, STAT5A, CCND2
hsa-miR-519e-3p AKT2, AKT1, STAT3, STAT5A, IKBKG, NF2
hsa-miR-521 AKT1, PIK3R1, STAT5A, CBL, CCND2
hsa-miR-550a-3p AKT1, CSF3, JAK3, STAT3, CASP7, DFFA, DFFB, EXOG, IKBKB, IRAK4, PPP3R1, PRKAR2A, IL10RA, IL28RA, IL2RB, PRKAR2A,
IL6R
hsa-miR-617 IL11, IL19, IL4R, LIF, PRLR, SOCS7, IL15, IL6R, AKT2, IL21R, STAM2, STAT3, IKBKG, XIAP
hsa-miR-644a AKAP13
hsa-miR-934 CSF3, IL11RA, LIF, PTPN11, SOCS2, PIK3R2, AKT3, OSM, TYK2, APAF1, CASP7, IL1R1, SERF2, TRAF2
hsa-miR-147b XIAP, PIK3CG, STAT5B, CCND1, CCND3, CISH, CLIC6, IL19, JAK1, SPRED1, TYK2
hsa-miR-33a-3p IL15, EXOG
hsa-miR-146b-5p AKT1
hsa-miR-19a-5p CBL
hsa-miR-26a-1-3p AKT2, TYK2, PIAS3
hsa-miR-493-5p AKAP13, KIT
hsa-miR-562 IKBKB, ADAM17, NMI, TGFB1, TNFSF13B, PTK2, AKT2, CSF3, KIT
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Table 1 Lists the experimentally validated novel microRNAs and their putative targets in different signaling pathways
at EL −25 ΔG kcal/mol (Continued)
b.
Novel miRNA Targets (MAPK) Targets
(NOTCH)
Targets (VEGF) Targets (Wnt)
hsa-miR-296-3p F2RL1, NFATC2, EPHB4 EPHB4 F2RL1, NFATC2 NFATC2, VANGL1
hsa-miR-296-5p APC, CSPG4 - AQP1 ZEB2, APC
hsa-miR-339-3p WEE1, FLNA - - CACYBP
hsa-miR-491-5p PDGFRA, XIAP, KAT6B - LRP6, PDGFRA XIAP, LRP6
hsa-miR-770-5p - MAGEA1 RBM39 -
hsa-miR-941 - - STAT5A -
hsa-miR-15a-3p ARF1, WNT5A - RBL2 SETD8, WNT5A,
VIM
hsa-miR-141-5p FLOT1 - IL17F SULF1
has-miR-148b-5p LRP1 - LRP1, KCNH1, DNMT1 LRP1, PLCB2
has-miR-17-3p CXADR, DUSP22, PLK1 GDPD5 PLK1 -
has-miR-188-3p YWHAZ MUC16,
GLI1
GLI1, PIK3R2, PIK3R2 GLI1
has-miR-218-2-3p FGF4, TNC - TNC CSNK1E, PLCB2
has-miR-219-1-3p NOS2 - NOS2 CHST11
has-miR-24-1-5p NRG1 - NRG1 -
has-miR-329 CDH13 JAK3 JAK3 -
has-miR-337-5p RARA, MVP, DUSP22, VEGFA, ABCA1, GRIN1, MAPK12,
F10, BCL6, IGFBP5
CDKN1A,
NCSTN,
VEGFA,
WNT3A
VEGFA, MAZ, LIMK1, MAPK12,
F10, COL1A1, PIK3R1, IL15,
IGFBP5
AXIN2, MBD2,
CDH11, WNT3A,
BCL6
has-miR-506-3p - - - CCND2
has-miR-519e-3p NFKB2, RARA, NF2, TFF2, ARRB2 ARRB2 - ARRB2, NF2
has-miR-521 - - NFATC1 NFATC1
has-miR-550a-3p DYNLL1, IL6R LFNG IL6R, IL15 ING4, SFRP5
has-miR-617 OCLN, LRP1, NDFIP1, TIMP1 NCOR1 OCLN, MMP2, LRP1, TIMP1,
ARF6
LRP1, TIMP1
has-miR-644a - - - CUX1
has-miR-934 KCNMA1 GLI1 GLI1, APEX1 GL1
has-miR-33a-3p FLT4 FLT4 FLT4 AXIN1
has-miR-146b-5p NFATC2, XIAP - NFATC2 XIAP, NFATC2
has-miR-26a-1-3p AGER, ERBB, ACAT1, CXCR2, PRMT1, SMAD3,
APOBEC3G, RRAS, PLAUR, LRP1, PGR, ERBB3, MAPK12,
TRAF4,
NOS3,
NOTCH4,
PLAUR,
FURIN
AGER, NOS3, NOTCH4, PARG,
PLAUR, ERBB3, LRP1, CD47,
MAPK12, FURIN, SMAD3
LRP1, ERBB3,
MCC, SCN5A,
PRMT1, ZNF703,
SMAD3
has-miR-493-5p PODXL, GRIN1, KIT, TGFB3 - MUC1, KIT FERMT2, IGF2BP1,
PLCB2
has-miR-562 CDH5, PTK2, FLNA, SP1, CSF3, TGFB1, NFATC2, CD36,
ERCC1, ADAM17, ARRB1, NGFR, HSPB1, MAP3K11,
PTK2, TNFSF13B, APOB, KIT, CSF3, AKT2, TRAF2, ELK1,
CD274, CAMK2B
ADAM17,
ARRB1,
TGFB1
ADAM17, APOB, HSPB1, PTK2,
CSF3, AKT2, CDH5, TGFB1,
NFATC2, PPARA, VASH1, SP1,
KIT
CHST11, TGFB1,
NMI, FXYD5,
NFATC2, CAMK2B
a. The genes targeted by these miRNAs in the Jakstat pathway. b. represents those genes targeted in Mapkinase, Notch,Vegf and Wnt signaling pathways.
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ingly, a number of microRNAs were found to target this
gene at its 3′UTR, 5′UTR, exons, or both 3′UTR & 5′
UTR or both 3′UTR & exons. The microRNAs targetingthe 3′UTR of Dvl3 showed a phylogenetic relationship
when their sequences were aligned using ClustalX
(Figure 5b). Regulation of Dvl3 by these sets of microRNAs
was also deciphered using GeneGo MetaCore (Figure 5c).
Figure 3 Interaction and enrichment analysis of the novel miRNA. a. The interaction of novel miRNAs with various signaling molecules
reveals positive and negative regulation with downstream effector molecules as shown by MetaCore analysis. Red arrow indicates a down
regulation whereas green arrow indicates up regulation of a particular pathway by the given miRNA ( generic binding protein; microRNA;
- Transcription factor; - receptor ligand; - generic enzyme; - protein and - regulators). b. Histogram representing enrichment analysis
of these novel miRNAs in different diseased conditions in humans. c. The spectrum of novel miRNAs involved in GM-CSF signaling. d & e.
Enrichment analysis of miRNAs and their targets shows the list of different signaling networks they are involved and are deregulated in
different carcinomas.
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Figure 5 Schematic representation of miRNA targets deciphered by miRanda and miRNA interaction with Dvl 3 target gene.
a. Represents percentage target hits by miRNAs of different pathway genes at 5'UTR, exons and 3'UTR compiled in oncomiRdbB. b. shows an
example where several miRNAs are targeting Dvl3 gene at its various positions. c. Network interaction of miRNAs in regulating Dvl3 target gene.
d. Shows miRNA let-7b targeting multiple genes at different positions, 5'UTR, 3'UTR and exons.
Figure 4 MiRNA target identification at various energy levels in different pathways. a. Target identification of microRNAs at 3 different
energy levels was performed on the retrieved sequences from different oncogenic signaling pathways using miRanda. b. shows the percentage
cooperation of different microRNA targets of these pathways involved in the development of breast cancer.
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http://www.biomedcentral.com/1471-2105/15/15On the other hand, single miRNAs hitting multiple targets
at various genomic locations such as 3′UTR, 5′UTR and
exons were also identified. One example, miR-let-7b, had
multiple targets at all positions as shown schematically in
Figure 5d. Those microRNAs targeting exons and 5′UTR
were seen to target key regulators of oncogenic signaling
pathways (Additional file 2: Figure S2). The interaction be-
tween such microRNAs and their targets in various signal-
ing pathways were delineated using GeneGo MetaCore.
The microRNA-target networks and hubs and their the-
rapeutic targets were also deciphered (Figure 3a and
Additional file 3: Figure S3a and b).
Generation of pathway maps using enrichment analysis
Enrichment analysis was performed for the predicted
microRNAs and their targets to further support their in-
volvement in breast cancer development in both human
and mouse using GeneGo MetaCore. This analysis sta-
tistically enriched the miRNAs and their targets with
the available dataset in GeneGo MetaCore and gener-
ated p-values where high negative log p-values of
microRNAs and their targets reflected significant asso-
ciation with breast oncogenesis. The enrichment analysis
also supported our percentage co-operative analysis of dif-
ferent oncogenic pathways in breast cancer development
and progression (Figure 3b and c). Similarly, further en-
richment analysis for relative expression of these novel
miRNAs in different disease conditions in humans
showed the highest score for immunoproliferative disor-
ders followed by lymphoproliferative disorders (Figure 3d).
The spectrum of miRNAs was found to be crucial in
GM-CSF signaling as depicted by the pathway maps gen-
erated using MetaCore software (Figure 3e).
OncomiRdbB database structure
OncomiRdbB is fully designed and developed as a web
interface where Perl-CGI is used to connect the Apache
web server which works as a back-end to generate dy-
namically user friendly HTML front end queries, an
open-source graphics system that compiles into java
code. OncomiRdbB provides easy search options for
users to retrieve meaningful information of oncomiRs of
two different genomes, their mature sequences, acces-
sion no, their respective targets in different oncogenic
pathways, location in chromosome and their respective
genes. Users can search query by name, accession no,
target gene and sequence of miRNAs. It also facilitates
downloading of specific microRNAs along with their tar-
get details or the complete list of microRNAs and their
target information depending on the query. It provides
useful interaction data for these microRNAs and their
targets in various signaling pathways at the 3′UTR, 5′
UTR and exons. Finally this database also provides links
to the parental biological databases from which theinformation is retrieved. OncomiRdbB is hosted on the
web and is freely accessible to those who wish to retrieve
the information compiled in this database.
Utility and discussion
MicroRNAs are involved in the regulation of important
signaling pathways by controlling the expression of a
variety of oncoproteins which are responsible for cancer
development and progression [23]. A few existing data-
bases listed these microRNAs and their association with
many diseases, including different cancers from diverse
organisms as described above. However, none of these
specifically describe the class of oncomiRs and their tar-
gets for a given cancer. Due to the lack of a properly
compiled database, these data remain under utilized.
Therefore, we present here a database, OncomiRdbB
(OncomiR database for Breast cancer), which contains
all the mined and compiled information along with ~400
validated oncomiRs of breast cancer. We also report
additional novel oncomiRs experimentally identified in
human cancer samples, along with their specific target
genes. Compared to miRBase, PhenomiR and miR2Disease,
OncomiRdbB collates significantly more microRNAs and
their targets in both human and mouse. Thus OnmiRdbB
provides better compiled information regarding the
oncomiRs involved in breast cancer.
MicroRNAs with oncogenic or tumor-suppressive func-
tion are capable of modulating several targets in multiple
genetic pathways. Mouse models are the predominant
mammalian platform chosen to model cancer and as such
they represent ideal platform to study the microRNA can-
cer association in human and to validate targets [24]. With
this premise, we performed sequence alignment using Clus-
talX in order to find any evolutionary relationships which
would suggest functional similarity between these miRNAs.
Most of the miRNAs of human and mouse formed tight
phylogenetic clusters. Comparative cluster analysis add-
itionally confirmed that these miRNAs have common bio-
logical functionality and possess similar mechanisms of
action in breast cancer. This analysis also interrogated any
conserved functional relationships in the development
of breast cancer. For example, hsa-miR-145, hsa-miR-
151-3p and hsa-miR-30 showed sequence and func-
tional similarity with mmu-miR-145, mmu-miR-151-3p
and mmu-miR-30 respectively.
MicroRNA target identification is an important step in
determining its specific roles in regulating a cellular
process. MicroRNAs are known to regulate mRNAs
post-transcriptionally by binding at the 3′ UTR. How-
ever, miRNA target prediction in animals is still in its
infancy due to limited knowledge about parameters
involved in the interaction between miRNAs and their
target. Also, the uneven distribution of miRNA binding
Khurana et al. BMC Bioinformatics 2014, 15:15 Page 10 of 12
http://www.biomedcentral.com/1471-2105/15/15locations within the target transcript poses a further
challenge to the sensitivity and efficiency of computa-
tional prediction [25]. Therefore, finding a consistent
microRNA target across different miRNA target predic-
tion tools is a challenging task [26]. In this study we
used miRanda at different energy levels and PicTar and
TargetScan algorithms to minimize the false positive
rates during miRNA target prediction. Apart from the
complementarity between the mRNA and miRNA, the
miRanda algorithm also takes into account the weighted
sum of match and mismatch scores for base pairs and
gap penalties, allowing one wobbling pair in the seed re-
gion. Thus, use of this algorithm takes into consider-
ation different characteristics of the miRNA-mRNA
interaction [27]. The miRanda program predicted ‘per-
fect’ pairing of miRNA-mRNA at lower energy (EL-25)
levels, while not ‘so-perfect’ pairing at higher energy
levels (EL-15). Thus, miRNA-target prediction at differ-
ent energy levels will help users to identify putative tar-
gets of all miRNAs and also aid validation of specific
breast cancer targets in both genomes.
In OncomiRdbB, a total of 711 human and 490 mouse
targets are listed which is high compared to the targets
listed in other databases. One of the additional features
of OncomiRdbB is that these targets are also classified
based on various oncogenic signaling pathways which
is not yet available in other databases. McCubrey
et al., [28] have shown that there is interaction among
Ras/Raf/MEK/ERK/PI3K/PTEN and Akt pathways dur-
ing carcinogenesis. Likewise, cooperative interaction of
Notch and Ras/MAPK pathway in human breast car-
cinogenesis and hepatocarcinogenesis was demonstrated
by Fan et al., [29]. Therefore, the percentage cooperative
analysis was carried out to address the role of miRNAs
in deregulating multiple oncogenic pathway genes in
breast cancer development along with the percentage of
target hits by the miRNAs among the total number of
targets present in each pathway. Around 30–50 percent
target hits in Notch, VEGF, Wnt, Apoptosis, MAPKinase
and JAK-STAT pathways indicated a significant inter-
vention by oncomiRs in these pathways during breast
cancer development. Although the exact percentage co-
operative analysis has not been demonstrated, it is
evident that these miRNAs are deregulating various
oncogenic pathways. The information generated also led
to the identification of candidate microRNAs regulating
multiple therapeutic targets to combat breast cancer
effectively.
Although the majority of miRNAs have been reported
to target the 3′UTR, Zhou et al., [30] identified miRNAs
targeting coding region and 5′ UTR, but these were less
represented and less effective in translation repression.
Inhan et al., [31] showed that while most of the miRNAs
interact with 3′UTR of the target genes with its 5′end, asmall proportion of miRNAs binding to 5′UTR use the
3′end for effective interaction. Hence, in order to define
the interacting locations of miRNAs within the target
genes, 3′UTR, 5′UTR and exon sequences were down-
loaded and used for target location identification. This
analysis indicated that majority (around 70%) lie in the
3′UTR, whilst 10% miRNAs target the 5′UTR, 10% tar-
geted exons, 5% of miRNAs targeted exons at their
3′ and 5′ UTR respectively within the gene and the
remaining 5% targeted 5′UTR, 3′UTR & exons. Interaction
between miRNAs and their targets was analyzed using the
‘R’ algorithm. Through this statistical analysis program, it
was observed that either multiple targets are being con-
trolled by a single miRNA or that several miRNAs target
single transcripts. Nevertheless, the former situation was
found to be a more common phenomenon than the latter.
Dvl3 is one example of a target gene where several miRNAs
act at the 3′UTR, 5′UTR and exons. A phylogenetic clus-
tering of the 3′UTR miRNAs indicated a conserved func-
tional relationship amongst them. On the other hand, we
observed that a single miRNA, let-7b, hit multiple targets of
several oncogenic pathways at their 3′UTR, 5′UTR and
exons. It was also observed that targets with location in
5′UTR and exons were the key players of oncogenic
pathways.
The interaction of miRNAs and their respective targets
was deciphered using the GeneGo MetaCore software
suite to identify miRNAs with multiple potential targets
for therapeutic intervention in breast cancer. The inter-
active networks and hubs revealed functional co opera-
tivity of several miRNAs and target groups in the
various signaling pathways. Engels et al., [32] also dem-
onstrated that several miRNAs bind at 3′UTR targets
and inhibit translation via co-operative actions [33]. Our
analysis also corroborated with this and revealed the
possibility of using multiple targets for possible thera-
peutic intervention. To the best of our knowledge, infor-
mation on the cooperative interaction of miRNAs and
their targets is a unique feature of OncomiRdbB. To
support the authenticity of our database as specific to
breast cancer, we have performed enrichment analyses
of miRNAs and their targets from different oncogenic
signaling pathways and provided the degree of relevance
of miRNAs and their targets based on p-values, where
lower p-values were assigned higher priority (GeneGo
MetaCore software). These p-values indicated the prob-
ability of a given number of miRNAs and target genes
matching with a certain number of miRNAs and target
genes responsible for given disease and signaling path-
ways available in the GeneGo MetaCore suite. The target
enrichment analysis supported our hypothesis that there
is co-operation among different oncogenic pathways
during cancer progression and it also indicated the ex-
tent of their potential involvement in cancer progression.
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man and mouse could be an acceptable methodology for
probing breast cancer miRNAs interrelationships.
We have experimentally validated our database by 2
different array platforms using human breast cancer
samples. Approximately 400 miRNAs were valid and sig-
nificant in one or the other stage/grade. In addition to
these, this approach identified 34 novel miRNAs which
are not yet reported as breast cancer miRNAs in any of
the databases so far. The target identification of these
novel miRNAs using miRanda algorithm at 3 energy
levels together revealed 162 gene targets. The interaction
between the novel miRNAs and their respective tar-
gets using MetaCore software delineated the networks
and the hubs involved in various oncogenic signaling
pathways. Anti-apoptotic molecules such as BCLXW,
BCL-Xl were found to be down regulated by the novel
miRNAs identified in this study (as predicted by GeneGo
pathway), indicating possible roles of these miRNAs in de-
velopment of cancer and metastatic progression. For
example, miR-337-5p, miR-17-1, miR-15a, miR-491-5p,
miR-339, miR-337-3p, miR-241, miR-19a were found to
modulate oncogenic targets including TGFβ, STATs,
c-MYC and SMAD. Taken together, this established a
clear mechanistic interaction underlying miRNA deregula-
tion and tumorigenesis.
Our data also indicated potential functional coopera-
tivity of miRNAs and their targets in the development of
breast cancer [34]. Hence our finding of cooperation
among pathways was supported by the GeneGo MetaCore
pathway interaction enrichment analysis. Moreover, we
have also deciphered various potential therapeutic targets
and their networks. More recently, it has been shown that
circulating miRNAs are potential biomarkers for the de-
tection and subsequent staging and grading of breast can-
cer [35,36]. Unsupervised hierarchical cluster analysis of
the miRNA expression between cancerous and normal tis-
sue samples from patients showed major differences in
miRNA expression. This study provides a basis for the
blood-borne testing of miRNAs as biomarkers for the de-
tection and subsequent staging of breast cancer. Thus, the
in silico cum experimental validation data regarding the
novel miRNA generated using OncomiRdbB could be
used for future miRNA-based biomarkers and/or targeted
therapeutics.
Conclusions
OncomiRdbB is designed as a comprehensive user
friendly database which lists miRNAs and their respect-
ive targets for breast cancer in both the human and
mouse. We have experimentally validated ~400 miRNAs
in human breast cancer tissues and found 34 miRNAs
which are as yet unreported. Users can retrieve informa-
tion using miRNA name, sequence, accession no., genename, organism or simply cancer type. OncomiRdbB
gives details about the target genes, their chromosome
location and position of the miRNA hits within the gene
from various oncogenic signaling pathways. This is the
first attempt to delineate the complicated interaction
network involving different miRNAs and their targets in
five oncogenic signaling pathways for breast cancer.
OncomiRdbB is a central resource for cancer biologists
and clinicians for further experimental validation of
these targets and will also help clinicians in the selection
of potential candidates for the development of novel
clinical biomarkers and ultimately novel therapeutic
interventions.
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